Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-04-10

Avalo Therapeutics (AVTX)

CEO Garry Neil was paid $3,807,581 in fiscal year 2025, ↓ down 47.2% from fiscal year 2024 (SEC filing 0001534120-26-000022 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,807,581 ↓
Garry Neil total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
99.71%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Garry Neil (Chief Executive Officer, President and principal executive officer), FY2025 total compensation $3,807,581 (base salary $590,000) [exec_comp, SEC accession 0001534120-26-000022, filed 2026-04-10]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

AVTX's next annual pay disclosure, estimated March 20, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Garry Neil$590,000—$0$2,732,298$474,950—$10,333$3,807,581
Chief Executive Officer, President and principal executive officer
Taylor Boyd116,250003,049,48152,08001,9403,219,751
Chief Business Officer
Mittie Doyle512,500—01,030,429229,600—8,0281,780,557
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Garry Neil$3,807,581$7,212,749$1,075,362↓ −3,405,168
Taylor Boyd3,219,751———
Mittie Doyle1,780,557———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Avalo Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AVTX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against AVTX
No companies currently name AVTX as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Garry NeilCEO$3,807,581
Mittie DoyleChief Medical Officer$1,780,557
Taylor BoydChief Business Officer$3,219,751
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Aaron KantoffIndependent Director$128,973
Gilla Kaplan, Ph.DIndependent Director$126,955
Jonathan Goldman, M.DIndependent Director$128,473
June Almenoff, M.D., Ph.DFormer director (through FY2025)$367,731
Kevin LindIndependent Director$456,488
Michael HeffernanChair of the Board$509,578
Mitchell ChanIndependent Director$133,991
Rita Jain, M.DIndependent Director$177,579
Samantha TruexIndependent Director$127,473
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mittie DoylePSU72,500—$1,316,600
Garry NeilPSU167,000—3,032,720
Garry NeilRSU129,733—2,355,951
Garry NeilRSU278—11,462
Garry NeilOption281,4759.88—
Garry NeilOption411,0008.04—
Taylor BoydOption275,00012.96—
Mittie DoyleOption151,12512.65—
Mittie DoyleOption155,0008.04—
05

Incentive-plan design — the Compensation Discussion & Analysis

Compensation is designed to attract and retain individuals with superior talent, motivate employees to achieve short- and long-term results in the best interests of stockholders, and reflect a long-term commitment to the Company.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantRadford, an Aon Company
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-178,003,14223,2852,23699.71%Passed
20222022-06-1466,230,2634,535,881482,75492.96%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-06-1799.71%a
20222022-06-1492.96%b

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Majority of shares present and entitled to vote | Abstentions: Abstentions will have the same effect as a vote against this Proposal 3.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Michael HeffernanIndependent · Board Chair$61,573$0$448,005——$509,578
Kevin LindIndependent · Audit (Chair) · Compensation00456,488——456,488
June Almenoff, M.D., Ph.DIndependent · Audit · Departed during FY47,91761,810258,004——367,731
Rita Jain, M.DIndependent · Audit2,1960175,383——177,579
Mitchell ChanIndependent · Audit · Not standing for re-election63,018070,973——133,991
Aaron KantoffIndependent · Compensation (Chair) · Nominating and Corporate Governance58,000070,973——128,973
Jonathan Goldman, M.DIndependent · Science and Technology Advisory Committee · Not standing for re-election57,500070,973——128,473
Samantha TruexIndependent · Compensation · Nominating and Corporate Governance (Chair)56,500070,973——127,473
Gilla Kaplan, Ph.DIndependent · Compensation · Nominating and Corporate Governance · Science and Technology Advisory Committee55,982070,973——126,955
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 13,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$402,686
Equity awards (grant-date value)$61,810
All other compensation$0
Total cost of the board$464,496

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Avalo Therapeutics2025Garry Neil$590,000$0$2,732,298$474,950$3,807,581

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Avalo Therapeutics in fiscal 2025?
As disclosed, Garry Neil (Chief Executive Officer, President and principal executive officer) was the highest-paid executive at Avalo Therapeutics in fiscal 2025, with total compensation of $3,807,581.
How did shareholders vote on Avalo Therapeutics's executive compensation?
As disclosed, 99.71% of shareholders supported Avalo Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Avalo Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Avalo Therapeutics reported total board compensation of $464,496 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Garry NeilDEF 14A2026-04-100001534120-26-000022Section “Summary Compensation Table” · page 31. As printed: 3,807,581. Filing ↗
2Section 01, Taylor BoydDEF 14A2026-04-100001534120-26-000022Section “Summary Compensation Table” · page 31. As printed: 3,219,751. Filing ↗machine: r6 · c42 · span 409211–409221
3Section 01, Mittie DoyleDEF 14A2026-04-100001534120-26-000022Section “Summary Compensation Table” · page 31. As printed: 1,780,557. Filing ↗
4Section 07, pay ratio10-K2026-03-230001534120-26-000011Section “CEO Pay Ratio”. As printed: —. Filing ↗
5Section 08, Michael HeffernanDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 509,578. Filing ↗machine: span 260896–261156
6Section 08, Kevin LindDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 456,488. Filing ↗machine: span 271361–271593
7Section 08, June Almenoff, M.D., Ph.DDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 367,731. Filing ↗machine: span 262572–262804
8Section 08, Rita Jain, M.DDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 177,579. Filing ↗machine: span 267114–267346
9Section 08, Mitchell ChanDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 133,991. Filing ↗machine: span 264020–264252
10Section 08, Aaron KantoffDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 128,973. Filing ↗machine: span 268574–268806
11Section 08, Jonathan Goldman, M.DDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 128,473. Filing ↗machine: span 265477–265709
12Section 08, Samantha TruexDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 127,473. Filing ↗machine: span 273122–273354
13Section 08, Gilla Kaplan, Ph.DDEF 14A2026-04-100001534120-26-000022Section “Director Compensation”. As printed: 126,955. Filing ↗machine: span 270028–270260
14Section 06, 2025 voteForm 8-K2025-06-170001628280-25-031818Item 5.07 · say-on-pay result. As reported: 99.71% (votes for as printed: 8,003,142). Filing ↗
15Section 06, 2022 voteForm 8-K2022-06-140001628280-22-017110Item 5.07 · say-on-pay result. As reported: 92.96% (votes for as printed: 66,230,263). Filing ↗
16Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
17Section 09b board cost (computed)Computed——Cash 402,686 + equity 61,810 + all other 0 = 464,496, summed across the director compensation table rows.machine: formula: Σ = 464,496
18Avalo Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-100001534120-26-000022CEO total compensation as printed in Avalo Therapeutics's own proxy. As printed: 3,807,581. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.